Slingshot members are tracking this event:
AbbVie Receives FDA Accelerated Approval of Venclexta (venetoclax) Tablets, the First BCL-2 Inhibitor in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Deletion
Do you think this event is important to the companies below? How will it affect their stock price?
- Important new treatment option for patients with difficult to treat form of CLL(2)
- The approval of Venclexta reinforces AbbVie's growing position in hematologic oncology
Slingshot Insights Explained
Apr 11, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Venclexta, Venetoclax, Bcl-2 Inhibitor, Chronic Lymphocytic Leukemia Patients